Helix, a population genomics and COVID-19 testing company, has closed on its Series C funding round led by existing investors Warburg Pincus, DFJ Growth, Kleiner Perkins Caufield Byers, Mayo Clinic and Temasek.

Helix's end-to-end genomics platform enables organizations to advance genomic research and accelerate the integration of genomic data into clinical care through its unique 'Sequence Once, Query Often' model. With this model, an individual's DNA can be collected, sequenced and securely stored once